Skip to main content
TIBET AIM PHARM. INC. logo

TIBET AIM PHARM. INC. — Investor Relations & Filings

Ticker · 002826 ISIN · CNE100002C39 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,084 across all filing types
Latest filing 2025-01-08 Legal Proceedings Report
Country CN China
Listing Shenzhen Stock Exchange 002826

About TIBET AIM PHARM. INC.

https://www.emyy.cn

Tibet Aim Pharm. Inc. is a pharmaceutical enterprise focused on the research, development, production, and distribution of medicinal products. The company integrates traditional Tibetan medicine with modern pharmaceutical manufacturing processes to develop a diverse portfolio of treatments. Its core product range typically includes cardiovascular medications, digestive system therapies, and specialized herbal formulations derived from high-altitude botanical sources. Tibet Aim Pharm. Inc. emphasizes the modernization of traditional formulas through rigorous clinical testing and standardized production techniques. The company serves healthcare providers and patients by providing therapeutic solutions that bridge ancient medical knowledge with contemporary scientific standards.

Recent filings

Filing Released Lang Actions
北京植德律师事务所关于西藏易明西雅医药科技股份有限公司2024年限制性股票激励计划首次授予事项的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the company's 2024 restricted stock incentive plan's first grant. It details the legal compliance, approvals, adjustments, and conditions related to the stock incentive plan. It is not a financial report, earnings release, or management discussion. It is a legal proceeding related document providing a formal legal opinion on a corporate action (stock incentive plan). Therefore, it fits best under Legal Proceedings Report (LTR). The document length (6678 characters) and content confirm it is a substantive legal opinion, not a brief announcement or certification.
2025-01-08 Chinese
第三届监事会第二十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 20th meeting of the third Supervisory Board of the company. It details the meeting attendance, the agenda items discussed, and the voting results on stock incentive plan adjustments and stock grants. There are no financial statements or detailed financial data presented, nor is this a report or presentation. It is a formal meeting resolution announcement related to management decisions on stock incentives. This fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies. The document length is short (1349 characters), and it is not an announcement of a report publication or a certification. Therefore, the classification is MANG with high confidence.
2025-01-08 Chinese
2024年限制性股票激励计划首次授予激励对象名单（授予日）
Capital/Financing Update Classification · 95% confidence The document is titled as a list of recipients for a 2024 restricted stock incentive plan, detailing the allocation of restricted shares to various executives and core management personnel. It includes specific share quantities, percentages of total shares, and roles of the recipients. This is a disclosure related to share-based compensation and equity incentives for management and key employees. It is not a financial report, earnings release, or regulatory certification. It is an announcement of a share-based incentive plan allocation, which fits best under the category of Capital/Financing Update (CAP), as it relates to changes in the company's capital structure through stock incentives.
2025-01-08 Chinese
第三届董事会第二十二次会议决议公告
Board/Management Information Classification · 100% confidence The document is an announcement of resolutions passed at the 22nd meeting of the third board of directors of the company. It details the meeting attendance, the approval of adjustments to the 2024 restricted stock incentive plan, and the granting of restricted stock to incentive recipients. It includes voting results and references to legal opinions and related announcements. The content focuses on board decisions and management matters, specifically about stock incentive plans and related approvals. There is no financial report, earnings data, or regulatory filing of financial results. The document is clearly about board/management information, specifically board meeting resolutions and decisions.
2025-01-08 Chinese
关于调整 2024 年限制性股票激励计划相关事项的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding adjustments to the 2024 restricted stock incentive plan of the company. It details board and supervisory committee meetings, approvals, legal opinions, and changes in the number of incentive recipients and shares granted. The content focuses on corporate governance and compensation plan adjustments rather than financial results or detailed financial statements. It is not a full annual or interim report, nor an earnings release. It is not a proxy solicitation or voting result announcement. The document is a formal announcement about management and board decisions related to stock incentives, which fits best under Board/Management Information (MANG). The document length is 2403 characters, which is relatively short and consistent with an announcement rather than a full report.
2025-01-08 Chinese
关于向2024年限制性股票激励计划激励对象首次授予限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the initial grant of restricted stock under a 2024 restricted stock incentive plan by the company 西藏易明西雅医药科技股份有限公司. It includes specifics about the grant date, number of shares, grant price, eligibility, performance conditions, approval procedures, legal opinions, and the impact on financials. The content focuses on the company's equity incentive plan and the granting of restricted shares to management and key personnel. This type of document is a formal announcement of a capital/financing update related to share-based compensation and equity incentives, rather than a full financial report or an earnings release. It is not a regulatory filing or a report publication announcement because it contains substantive details about the grant and approvals. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (7610 characters) supports it being a full announcement rather than a brief notice.
2025-01-08 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.